Recardio at BIO-EUROPE 2023

San Francisco, November 6, 2023 - Recardio Inc., a late stage clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, is participating in the BIO-EUROPE Conference 2023 in Munich.

The conference is an international forum to promote business development between pharmaceutical, financial and biotechnology companies. The event is Europe's largest partnering conference serving the global biotech industry. At this conference leading decision makers of the biotechnology, pharmaceutical and financial industry employed at emerging companies meet annually.

Recardio is presenting its latest advancements from its drug-based regenerative therapy clinical development program including its Phase 3 HEAL-MI study and will give a future outlook on new therapies and expansion programs.

BIO-EUROPE is taking place from November 6 to 8, 2023 in Munich, Germany.

About Recardio

Recardio Inc. is a late clinical-stage life science company focused on developing therapies for cardiovascular and other diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines critical for cardiac regeneration, resulting in healing cardiac tissue after an injury.

Recardio has received FDA and EMA clearance for a global pivotal phase III HEAL-MI clinical trial in acute myocardial infarction.  This trial is planned to initiate in 2025 and will serve as the basis to apply for market authorization in major global markets. Recardio plans to fully develop its therapeutic platform for patients with various cardiovascular diseases. The company is headquartered in San Francisco, California, with operations in both the US and Europe.

For more information, visit: www.recardio.eu or contact pr@recardio.eu